Secretory Microneme Proteins Induce T-Cell Recall Responses in Mice Chronically Infected with Toxoplasma gondii

^aC57BL/6 mice included 7 naive and 11 infected mice.

^bBALB/c mice included 6 naive and 12 infected mice.

Detection of IFN-γ production by intracellular cytokine staining.

To characterize T. gondii-specific CD4⁺ and CD8⁺ T-cell responses, splenocytes from naive and chronically infected mice were examined by intracellular staining for IFN-γ. Figure S1A in the supplemental material shows the gating strategy used for the intracellular staining for IFN-γ. In splenocytes from infected mice BALB/c mice stimulated with ESA, ∼14% of CD3⁺ IFN-γ⁺ cells were CD4⁺ T cells, while ∼4% were CD8⁺ T cells (Fig. S1B). Stimulation of splenocytes with MIC antigens resulted in significant increases in IFN-γ production by both CD4⁺ and CD8⁺ T cells from infected mice in comparison to that in naive mice, but CD4⁺ T cells produced greater amounts of IFN-γ than CD8⁺ T cells (Fig. 3). As expected, stimulation with ConA triggered IFN-γ production in both naive and infected mice (Fig. 3).

 

FIG 3

Intracellular cytokine staining of IFN-γ production by CD4⁺ and CD8⁺ T cells from BALB/c mice. Splenocytes were obtained from mice that were naive or chronically infected with T. gondii and stimulated with ESA (1 µg/ml), ConA (1 µg/ml), SUMO (1 µg/ml), MIC1, MIC4, or MIC6 (1 µg/ml), or MIC3 (0.5 µg/ml) for 24 h. The experiment was performed on 5 naive and 10 chronically infected mice. Ordinary one-way ANOVA with Sidak’s multiple-comparison test was used to compare results between naive and infected cells.

FIG S1

IFN-γ intracellular staining by splenocytes following in vitro stimulation. (A) Gating strategy for evaluation of CD4⁺ and CD8⁺ T cells producing IFN-γ. Figure represents IFN-γ intracellular staining from splenocytes obtained from BALB/c mice chronically infected with T. gondii when stimulated with 1 µg/ml of MIC1 protein for 24 h. (B) Percentages of CD4⁺ and CD8⁺ T cells among CD3⁺ IFN-γ⁺ splenocytes isolated from C57BL/6 and BALB/c mice stimulated with ESA or ConA. Download FIG S1, TIF file, 0.6 MB.

Copyright © 2019 Saraav et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

For C57BL/6 mice also, ESA-stimulated splenocytes from infected mice showed higher numbers of CD4⁺ T cells than CD8⁺ T cells among CD3⁺ IFN-γ⁺ cells (Fig. S1B). Stimulation of splenocytes with MIC antigens resulted in significant increases in IFN-γ production by CD4⁺ T cells from infected mice in comparison to those from naive mice (Fig. 4A). In contrast, most MIC antigens, with the exception of MIC1, did not show a significant difference in IFN-γ-producing CD8⁺ T cells (Fig. 4B).

 

FIG 4

Intracellular cytokine staining of IFN-γ production by CD4⁺ and CD8⁺ T cells from C57BL/6 mice. Splenocytes were obtained from mice that were naive or chronically infected with T. gondii and stimulated with ESA as an antigen-specific positive control (1 µg/ml), ConA as a nonspecific positive control (1 µg/ml), Sumo as a negative control (1 µg/ml), MIC1, MIC4, or MIC6 (1 µg/ml), or MIC3 (0.5 µg/ml) for 24 h. The experiment included 5 naive and 10 chronically infected mice. Ordinary one-way ANOVA with Sidak’s multiple-comparison test was used to compare results between naive and infected cells.

Analysis of IFN-γ production by memory T cells.

Memory T cells play a critical role in providing long-term immunity. During secondary challenge, populations of antigen-specific memory T cells have the capacity to mediate vigorous and accelerated responses. However, the relative contributions of different memory subsets (either CD4⁺ or CD8⁺ T cells) to recall responses to T. gondii antigens is unknown. To identify the frequencies of memory T-cell subsets producing IFN-γ in response to MIC antigens, we characterized memory T-cell subsets within CD4⁺ and CD8⁺ T cells. Figure 5A shows the gating strategy used for analyzing the four different T-cell populations, based on expression of cell surface markers CD44 and CD62L. We classified cells based on the expectations that central memory T cells are CD44^hi CD62L^hi, effector memory cells are CD44^hi CD62L^lo, effector T cells are CD44⁻ CD62L^lo, and naive cells are CD44⁻ CD62L^hi. For BALB/c mice, memory T-cell subset analysis was done both on CD4⁺ IFN-γ⁺ and CD8⁺ IFN-γ⁺ cells. Since in C57BL/6 mice IFN-γ was predominantly made by CD4⁺ T cells, memory T-cell subset analysis was done only on CD4⁺ IFN-γ⁺ T cells. We found that both in IFN-γ-producing CD4⁺ and CD8⁺ T cells in BALB/c mice and in IFN-γ-producing CD4⁺ T cells in C57BL/6 mice, Tem cells (CD44^hi CD62L^lo) were the predominant cells that contributed to IFN-γ production in response to MIC1 antigen (Fig. 5B). Similar results were obtained with MIC3, MIC4, and MIC6 (data not shown). Although the total number of memory cells was low, approximately 70 to 85% of CD4⁺ IFN-γ⁺ T cells and 58 to 70% of CD8⁺ IFN-γ⁺ T cells were CD62L^lo (Fig. 5B). These findings indicate that MIC antigen-experienced CD4⁺ and CD8⁺ T cells were maintained as effector memory cells in mice chronically infected with T. gondii.

 

FIG 5

Relative contribution of memory T-cell subsets to production of IFN-γ in response to MIC antigens. (A) The gating strategy for evaluation of CD4⁺ and CD8⁺ memory T-cell subsets producing IFN-γ using CD44 and CD62L markers is shown on the left. The plot on the right present the numbers (shown within the boxes) of CD4⁺ and CD8⁺ memory T-cell subsets producing IFN-γ in splenocytes obtained from BALB/c mice chronically infected with T. gondii when stimulated with 1 µg/ml of MIC1 for 24 h. (B) Frequencies of memory T-cell subsets producing IFN-γ in CD4⁺ and CD8⁺ T cells in response to MIC1 in splenocytes obtained from BALB/c and C57BL/6 mice chronically infected with T. gondii (n = 10). Since in C57BL/6 mice IFN- γ was predominantly made by CD4⁺ T cells, memory T-cell analysis was done on CD4⁺ IFN- γ ⁺ T cells.

Go to:

DISCUSSION

Excretory secretory antigens (ESA) of T. gondii play a key role in stimulation of antibody responses the host immune system during T. gondii infection (42). ESA also elicit strong delayed-type hypersensitivity reactions in humans, as detected by skin test, yet the antigens responsible for this response remain unknown (30, 43). Previous mass spectrometry studies done in our lab revealed ESA to be highly enriched in microneme proteins (29). Moreover, the secretory MIC1, MIC3, MIC4, and MIC6 proteins have been shown to induce protective immunity against T. gondii in the murine model (33, 34). In this study, we focused on the role of these secretory antigens in inducing immunological memory during chronic infection in the mouse. Our findings indicate that MIC proteins (MIC1, MIC3, MIC4, and MIC6) elicit cellular immune responses characterized by effector memory T cells that are activated to secrete IFN-γ. These findings suggest that MIC antigens may be useful for developing diagnostic methods that detect cell-mediated responses based on IFN-γ secretion.

Currently diagnosis of chronic toxoplasmosis is based almost entirely on antibody responses where chronic infections are best established based on IgG, while early infection is monitored by IgM (44,–49). Although standard serological tests provide excellent assessment of prior infection status, including discrimination between recently acquired and long-term infections, they do not provide an assessment of immunological responsiveness. As well, serological testing in newborns is complicated by the potential for transfer of maternal IgG antibodies. Consequently, it has been shown that testing of cell-mediated immunity in assays, such as detection of IFN-γ release by peripheral blood leukocytes, can provide greater discrimination of infection status in newborns (50, 51). These studies relied on whole parasite antigen, which performed well, but the authors commented that identification of specific antigens may improve test performance (50). In a very different patient population, IFN-γ-specific ELISPOT assays were used to estimate the risk of toxoplasmic encephalitis relapse in patients infected with HIV-1 and on highly active antiretroviral therapy (HAART) (49). Cell-mediated responses to T. gondii antigens in such patients may be a better predictor of the potential for reactivation of central nervous system (CNS) disease versus total CD4 levels that are normally monitored to assess immune status (49). This study was also based on using whole T. gondii soluble antigens from tachyzoites to detect immune status, and greater discrimination might be achieved using specific antigens.

Detection of IFN-γ secretion offers an independent means to assess prior infection, a method that has gained popularity recently for other chronic infections, such as tuberculosis (52,–54). An IFN-γ release assay known as T-SPOT TB and based on an ELISPOT test is one of the most sensitive methods used for detecting tuberculosis infection. This method is based on the ability of specialized immune cells (dendritic cells and macrophages) to present antigen on MHC class II receptors to memory T cells, which, in turn, produce IFN-γ. Previous studies using IFN-γ release assays to monitor IFN-γ secretion in T. gondii-infected mice indicate that responses to several GRA and ROP secretory antigens are detected very early after infection (55). Additionally, it has been shown that the parasite proteins GRA1 and SAG1 elicit production of IFN-γ from peripheral blood cells of chronically infected women (56). These findings suggest that it may be possible to develop assays to monitor IFN-γ release in response to specific T. gondii proteins as an alternative to serological assays for detecting both acute and chronic infections.

In this study, we developed an IFN-γ release assay based on the ELISPOT assay to quantify T-cell responses to recombinant MIC antigens found in ESA. Highly specific responses were detected from T cells from infected BALB/c and C57BL/6 mice stimulated with MIC1, MIC3, MIC4, and MIC6, suggesting that conserved MHC class II (MHC-II) epitopes are contained in these antigens. Based on ROC curve analyses, all four MIC antigens displayed very high sensitivity (100%) and specificity (86 to 100%). Of the MIC antigens tested, MIC1 showed the best combination of sensitivity and specificity. Hence, the IFN-γ ELISPOT assay using MIC1 or other antigens may be useful in detecting toxoplasma infection in other animals as well.

Although we have not tested ROC using crude ESA, the use of recombinant antigens offers several advantages. First, by using recombinant antigens, the production of material can be easily scaled and quality controlled from batch to batch. Second, it is evident from deconvolving the mixture of proteins found in ESA that not all antigens are capable of eliciting IFN-γ secretion responses. Hence, using purified recombinant antigens increases the specific activity of the assay. Finally, use of recombinant antigens may also allow avoidance of cross-reactive antigens, which would confound sensitivity and specificity performance.

Although our findings show promise for detecting infection in mice, there are several additional challenges that will need to be met if these studies are to be extended to other animals. First, it will be important to assess the degree to which MIC antigens are recognized across a broader panel of MHC-II receptors from different species. Second, the performance of the recombinant antigens described here may differ in sensitivity and/or specificity in the case of other animals, including humans. Finally, the performance of purified recombinant antigens as a means to detect infection based on IFN-γ stimulation may differ in acute infection versus chronic and for individuals of different immune statuses. Our studies stand as a benchmark for such future studies aimed at extending the utility of these antigens for diagnosis in other species, including humans.

During chronic T. gondii infection, long-term immunity is mainly mediated by T-cell production of IFN-γ required for controlling parasite reactivation (8, 57). Consequently, we also tested the ability of these four MIC antigens to induce IFN-γ production by CD4⁺ and CD8⁺ T cells in T. gondii-infected mice. In BALB/c mice, IFN-γ was found to be produced by both CD4⁺ and CD8⁺ T cells, although responses were higher in CD4⁺ T cells. This observation is in line with another study, in which CD4⁺ T cells were reported to produce more IFN-γ than did CD8⁺ T cells among splenocytes from chronically infected BALB/c mice stimulated with tachyzoite lysate antigen (58). We found that IFN-γ was primarily produced by CD4⁺ T cells in C57BL/6 mice. These results corroborate those of a previous study that reported CD4⁺ T cells as the main IFN-γ-producing cells among splenocytes obtained ex vivo from C57BL/6 mice immunized with T. gondii (59). The ability of MIC antigens to elicit IFN-γ secretion for both subtypes is consistent with previous findings indicating that these antigens can drive protective immune responses in the mouse (33,–35).

To decipher the phenotypes of memory T-cell subsets involved in IFN-γ production in response to MIC antigens, we characterized CD4⁺ and CD8⁺ T cells using phenotypic markers. We chose a time point of 4 weeks postinfection in order to avoid T-cell exhaustion, which has been described in other studies (60). Both CD4⁺ and CD8⁺ T cells producing IFN-γ in response to MIC antigens were found to be almost exclusively CD62L^lo cells, suggesting the presence of an extended pool of effector memory cells that produce IFN-γ in a recall response in T. gondii chronic infection. This result is consistent with the effector function of Tem cells, which, although short-lived (61), contribute to IFN-γ production and protection against chronic intracellular parasitic infections with Plasmodium chabaudi and Trypanosoma cruzi in the mouse (62,–64).

Taken together, our data demonstrate that MIC antigens found in ESA induce T memory recall responses that lead to IFN-γ secretion in animals chronically infected with T. gondii. Monitoring such responses may provide an adjunct to existing serological tests either to establish infection or to monitor immune responsiveness. Our findings also suggest that MIC antigens induce IFN-γ-producing CD4⁺ and CD8⁺ memory T cells that are maintained and activated against a secondary challenge; hence, these antigens might be exploited for development of protective vaccines.

Go to:

MATERIALS AND METHODS

Ethics.

Animal studies were conducted according to the U.S. Public Health Service policy on human care and use of laboratory animals. Animals were maintained in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care (66). Animal studies were approved by the Institutional Animal Studies Committee at the School of Medicine, Washington University, St. Louis, MO.

Parasite culture and preparation of ESA.

Toxoplasma strain RH tachyzoites were maintained in human foreskin fibroblasts as previously described (65). Excretory secretory antigens (ESA) were prepared as described previously, with slight modification (29). Parasites were harvested from fully egressed cultures and resuspended in extracellular (EC) buffer (5 mM KCl, 142 mM NaCl, 1 mM MgCl₂, 1.8 mM CaCl₂, 5.6 mM d-glucose, 25 mM HEPES [pH 7.4]). Tissue culture-grade 24-well plates were coated with 1% bovine serum albumin (BSA) in EC buffer at 4°C overnight. The next day, the wells were washed with EC buffer to remove BSA just prior to stimulating microneme secretion. For stimulation of ESA secretion, 500 µl of freshly harvested parasites was added to BSA-coated wells and 500 µl of 1 mM zaprinast (Sigma-Aldrich) in EC buffer was added. Parasites were allowed to secrete for 20 min at 37°C. After 20 min, plates were chilled for 5 min, the liquid was collected and centrifuged at 2,700 rpm and 4°C for 5 min, and the supernatant was retained as the ESA fraction. The ESA fraction was buffer exchanged with phosphate-buffered saline (PBS) using Amicon (Millipore Sigma) centrifugal filters (3-kDa cutoff), and the retained fraction was stored at −80°C. The protein concentration was estimated using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher).

Cloning, expression, and purification of MIC proteins.

MIC1, MIC3, and MIC4 constructs and M2AP, MIC6, and MIC10 full-length genes were amplified by PCR using T. gondii ME49 strain cDNA as the template with specific forward and reverse primers (Table S1). After treatment with the BsaI and XbaI restriction enzymes, PCR products were cloned into the pE-Sumo vector and transformed into competent E. coli DH10B. Positive clones were identified using colony PCR screening and confirmed by DNA sequencing. For expression of the Sumo fusion proteins, pE-Sumo-fusion plasmids were isolated from the DH510B cells and chemically transformed into E. coli BL21(DE3) Rosetta cells. A single pE-Sumo-positive colony was inoculated into TB broth with 100 µg/ml of ampicillin until the optical density reached between 0.6 and 0.8, and the culture was induced with 0.5 mM isopropyl-β-d-thiogalactopyranoside (IPTG) at 15°C overnight. Cells were harvested and the cell pellet was resuspended in lysis buffer (Sigma-Aldrich) containing lysozyme and protease inhibitor cocktail. Recombinant MIC proteins were purified using an HIS-Select nickel affinity gel (Sigma-Aldrich) using different concentration of imidazole. The purity of eluted proteins was analyzed by 12% SDS-PAGE electrophoresis and staining with Instant Blue Coomassie stain (Expedeon). Recombinant proteins were dialyzed against PBS (pH 7.2) and treated with Pierce high-capacity endotoxin removal resin (Thermo Fisher) for 8 to 12 h according to the manufacturer’s instructions. The recombinant MIC proteins were quantified by separation on SDS-PAGE gels, staining with Instant Blue Coomassie stain, and comparison with a standard curve of known concentrations of BSA. Samples were then stored at −80°C until use.

TABLE S1

List of the primers used in the study. Download Table S1, DOCX file, 0.1 MB.

Copyright © 2019 Saraav et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

Experimental design for in vivo infections.

Experiments were performed on 8-week-old specific-pathogen-free (SPF)-grade female BALB/c and C57BL/6 mice purchased from Jackson Laboratory. Studies were approved by Division of Comparative Medicine, Washington University. Animals were maintained in an AAALAC-approved animal facility. For chronic infection, mice were infected by oral administration of 5 to 10 cysts of T. gondii type II strain ME49. Enzyme-linked immunosorbent assay (ELISA) was performed using serum to confirm that the mice were infected. At 30 days postinfection, splenocytes were collected and stimulated with antigens.

Preparation of mouse splenocytes.

Spleens from naive and T. gondii-infected mice were harvested and splenocytes were released by grinding the spleen through a 70-μm-pore-size nylon cell strainer. Splenocytes were centrifuged at 400 × g for 10 min at 4°C, and red blood cells (RBCs) were removed using RBC lysis buffer (Biolegend) for 2 min on ice. Splenocytes were then washed in sterile PBS and Hanks’ balanced salt solution (HBSS; Corning). Cells were quantitated using a hemacytometer. For ELISPOT assay, splenocytes were resuspended in CTL medium (Immunospot) supplemented with 100 U/ml of penicillin and 100 μg/ml of streptomycin (M&C Gene Technology). For IFN-γ intracellular (cytokine staining) and phenotypic characterization, splenocytes were resuspended in RPMI 1640 medium (Gibco) and 10% heat-inactivated fetal bovine serum (HyClone).

IFN-γ ELISPOT assay.

Briefly, 2.5 × 10⁵ splenocytes per well were stimulated in precoated wells of polyvinylidene difluoride (PVDF) strip plates (Immunospot) with medium alone, ESA (1 μg/ml) for a positive control, concanavalin (ConA; Sigma-Aldrich; 1 μg/ml) for a nonspecific-T-cell positive control, Sumo (1 μg/ml) for a negative control, or different concentrations of MIC antigens (MIC1, 1 μg/ml; M2AP, 1 μg/ml; MIC3, 0.5 μg/ml; MIC4, 1 μg/ml; MIC6,1 μg/ml; and MIC10, 1 μg/ml) for 24 h at 37°C and 5% CO₂. After the plate was washed and developed according to the manufacturer’s instructions, the antigen recall response was determined by counting the number of spots (IFN-γ-producing cells) per well per treatment. The numbers of IFN-γ-producing T cells following stimulation with T. gondii antigens were detected and calculated using an ELISPOT reader (Immunospot S6 Core; CTL). Receiver operating characteristic (ROC) curves were used to evaluate the accuracy of the ELISPOT assay. Specificity, sensitivity, and cutoff values for MIC1, MIC3, MIC4, and MIC6 were determined for both BALB/c and C57BL/6 mice using the ROC curves.

Intracellular cytokine staining and immunophenotypic characterization.

Briefly, 2 × 10⁵ splenocytes per well were stimulated with concentrations of MIC antigens similar to those used in the previous experiment. After stimulation, cells were treated with GolgiStop protein transport inhibitor (1 μl/ml; BD Biosciences) for 6 h. Cells were washed and stained with 5 μl of LIVE/DEAD Aqua (Invitrogen) and 50 μl of anti-mouse CD3-allophycocyanin (APC)-Cy7, CD4-peridinin chlorophyll protein (PerCP)-Cy5.5, CD8-fluorescein isothiocyanate (FITC), CD44-phycoerythrin (PE), and CD62L-APC antibodies (Biolegend, USA) prepared in PBS plus 0.5% BSA for 30 min at 4°C in the dark. Cells were fixed and permeabilized with 200 μl of 1× BD Cytofix/Cytoperm buffer for 20 min at 4°C and then washed with 200 μl of 1× BD Perm/Wash buffer. Next cells were incubated with 50 μl of anti-mouse IFN-γ–PE–Cy7 intracellular staining antibody (Biolegend) or anti-mouse PE-Cy7 IgG1, ĸ isotype control (Biolegend), for 30 min at 4°C in the dark. Cells were washed and finally resuspended in 1× BD Perm/Wash buffer. Data analysis was carried out using FlowJo v10 software. Events were gated on singlets, live cells, and lymphocytes using forward scatter and side scatter. Analysis was done using isotype-matched controls as a reference. To identify the frequencies of memory T-cell subsets producing IFN-γ in response to MIC antigens in an ex vivo assay, gated CD4⁺ IFN-γ⁺ and CD8⁺ IFN-γ⁺ T cells were evaluated using CD44 and CD62L markers. Cells were acquired using a BD LSRII cytometer (BD Biosciences).

Statistical analyses.

Data were analyzed in Prism using the D’Agostino and Pearson test to confirm that they were normally distributed. Ordinary one-way analysis of variance (ANOVA) was used to compare ELISPOT results and IFN-γ-positive staining between naive and infected cells. P values of ≤0.05, ≤0.01, ≤0.001, and ≤0.0001 were considered statistically significant. The analyses were done by GraphPad Prism 7.0 software. ROC curves were used to evaluate the accuracy of the ELISPOT assay. The cutoff value was determined from the ROC curve by choosing the value that gave the best sensitivity and specificity.

Go to:

ACKNOWLEDGMENTS

We thank Jennifer Barks for assistance with cell culture and Keliang Tang and Yutao Qi for assistance with cloning of antigens.

This work was supported by a sponsored research agreement between Washington University and Lincoln Diagnostics, Inc.

The findings contained here are covered by a patent application from Washington University that is licensed by Lincoln Diagnostics, Inc. The funders had no role in the study design, collection of data, interpretation, or decision to submit the work for publication.

Go to:

REFERENCES

1. Jones JL, Dubey JP. 2012. Foodborne toxoplasmosis. Clin Infect Dis55:845–851. doi:10.1093/cid/cis508. [PubMed] [CrossRef] [Google Scholar]
2. Dubey JP, Miller NL, Frenkel JK. 1970. The Toxoplasma gondii oocyst from cat feces. J Exp Med132:636–662. doi:10.1084/jem.132.4.636. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Montoya JG, Remington JS. 1996. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis23:277–282. doi:10.1093/clinids/23.2.277. [PubMed] [CrossRef] [Google Scholar]
4. Luft BJ, Remington JS. 1992. Toxoplasmic encephalitis in AIDS. Clin Infect Dis15:211–222. doi:10.1093/clinids/15.2.211. [PubMed] [CrossRef] [Google Scholar]
5. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet363:1965–1976. doi:10.1016/S0140-6736(04)16412-X. [PubMed] [CrossRef] [Google Scholar]
6. Yap GS, Sher A. 1999. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology201:240–247. doi:10.1016/S0171-2985(99)80064-3. [PubMed] [CrossRef] [Google Scholar]
7. Mashayekhi M, Sandau MM, Dunay IR, Frickel EM, Khan A, Goldszmid RS, Sher A, Ploegh HL, Murphy TL, Sibley LD, Murphy KM. 2011. CD8alpha(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondiitachyzoites. Immunity 35:249–259. doi:10.1016/j.immuni.2011.08.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Khan IA, Ely KH, Kasper LH. 1994. Antigen-specific CD8+ T cell clone protects against acute Toxoplasma gondii infection in mice. J Immunol152:1856–1860. [PubMed] [Google Scholar]
9. Nathan CF, Murray HW, Wiebe ME, Rubin BY. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med158:670–689. doi:10.1084/jem.158.3.670. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Sibley LD, Adams LB, Fukutomi Y, Krahenbuhl JL. 1991. Tumor necrosis factor-alpha triggers antitoxoplasmal activity of IFN-gamma primed macrophages. J Immunol147:2340–2345. [PubMed] [Google Scholar]
11. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science240:516–518. doi:10.1126/science.3128869. [PubMed] [CrossRef] [Google Scholar]
12. Sturge CR, Yarovinsky F. 2014. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection. Infect Immun82:3090–3097. doi:10.1128/IAI.01722-14. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Parker SJ, Roberts CW, Alexander J. 1991. CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol84:207–212. [PMC free article] [PubMed] [Google Scholar]
14. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. 1991. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol146:286–292. [PubMed] [Google Scholar]
15. Shirahata T, Yamashita T, Ohta C, Goto H, Nakane A. 1994. CD8+ T lymphocytes are the major cell population involved in the early gamma interferon response and resistance to acute primary Toxoplasma gondii infection in mice. Microbiol Immunol38:789–796. doi:10.1111/j.1348-0421.1994.tb01858.x. [PubMed] [CrossRef] [Google Scholar]
16. Wang X, Kang H, Kikuchi T, Suzuki Y. 2004. Gamma interferon production, but not perforin-mediated cytolytic activity, of T cells is required for prevention of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease. Infect Immun72:4432–4438. doi:10.1128/IAI.72.8.4432-4438.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Sprent J, Surh CD. 2001. Generation and maintenance of memory T cells. Curr Opin Immunol13:248–254. doi:10.1016/S0952-7915(00)00211-9. [PubMed] [CrossRef] [Google Scholar]
18. Denkers EY, Gazzinelli RT. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev11:569–588. doi:10.1128/CMR.11.4.569. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Wilson DC, Grotenbreg GM, Liu K, Zhao Y, Frickel EM, Gubbels MJ, Ploegh HL, Yap GS. 2010. Differential regulation of effector- and central-memory responses to Toxoplasma gondii infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells. PLoS Pathog6:e1000815. doi:10.1371/journal.ppat.1000815. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Bhadra R, Gigley JP, Khan IA. 2011. The CD8 T-cell road to immunotherapy of toxoplasmosis. Immunotherapy3:789–801. doi:10.2217/imt.11.68. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature401:708–712. doi:10.1038/44385. [PubMed] [CrossRef] [Google Scholar]
22. Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol22:745–763. doi:10.1146/annurev.immunol.22.012703.104702. [PubMed] [CrossRef] [Google Scholar]
23. Carruthers VB, Giddings OK, Sibley LD. 1999. Secretion of micronemal proteins is associated with toxoplasma invasion of host cells. Cell Microbiol1:225–235. doi:10.1046/j.1462-5822.1999.00023.x. [PubMed] [CrossRef] [Google Scholar]
24. Carruthers VB, Sibley LD. 1997. Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts. Eur J Cell Biol73:114–123. [PubMed] [Google Scholar]
25. Carruthers VB, Sibley LD. 1999. Mobilization of intracellular calcium stimulates microneme discharge in Toxoplasma gondii. Mol Microbiol31:421–428. doi:10.1046/j.1365-2958.1999.01174.x. [PubMed] [CrossRef] [Google Scholar]
26. Carruthers VB, Moreno SN, Sibley LD. 1999. Ethanol and acetaldehyde elevate intracellular [Ca2+] and stimulate microneme discharge in Toxoplasma gondii. Biochem J342:379–386. doi:10.1042/bj3420379. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Cerede O, Dubremetz JF, Soete M, Deslee D, Vial H, Bout D, Lebrun M. 2005. Synergistic role of micronemal proteins in Toxoplasma gondii virulence. J Exp Med201:453–463. doi:10.1084/jem.20041672. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Marchant J, Cowper B, Liu Y, Lai L, Pinzan C, Marq JB, Friedrich N, Sawmynaden K, Liew L, Chai W, Childs RA, Saouros S, Simpson P, Roque Barreira MC, Feizi T, Soldati-Favre D, Matthews S. 2012. Galactose recognition by the apicomplexan parasite Toxoplasma gondii. J Biol Chem287:16720–16733. doi:10.1074/jbc.M111.325928. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Brown KM, Lourido S, Sibley LD. 2016. Serum albumin stimulates protein kinase G-dependent microneme secretion in Toxoplasma gondii. J Biol Chem291:9554–9565. doi:10.1074/jbc.M115.700518. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Decoster A, Darcy F, Capron A. 1988. Recognition of Toxoplasma gondii excreted and secreted antigens by human sera from acquired and congenital toxoplasmosis: identification of markers of acute and chronic infection. Clin Exp Immunol73:376–382. [PMC free article] [PubMed] [Google Scholar]
31. Duquesne V, Auriault C, Darcy F, Decavel JP, Capron A. 1990. Protection of nude rats against Toxoplasma infection by excreted-secreted antigen-specific helper T cells. Infect Immun58:2120–2126. [PMC free article] [PubMed] [Google Scholar]
32. Zenner L, Estaquier J, Darcy F, Maes P, Capron A, Cesbron-Delauw MF. 1999. Protective immunity in the rat model of congenital toxoplasmosis and the potential of excreted-secreted antigens as vaccine components. Parasite Immunol21:261–272. doi:10.1046/j.1365-3024.1999.00229.x. [PubMed] [CrossRef] [Google Scholar]
33. Lourenco EV, Bernardes ES, Silva NM, Mineo JR, Panunto-Castelo A, Roque-Barreira MC. 2006. Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Microbes Infect8:1244–1251. doi:10.1016/j.micinf.2005.11.013. [PubMed] [CrossRef] [Google Scholar]
34. Ismael AB, Sekkai D, Collin C, Bout D, Mevelec MN. 2003. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun71:6222–6228. doi:10.1128/IAI.71.11.6222-6228.2003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
35. Pinzan CF, Sardinha-Silva A, Almeida F, Lai L, Lopes CD, Lourenco EV, Panunto-Castelo A, Matthews S, Roque-Barreira MC. 2015. Vaccination with recombinant microneme proteins confers protection against experimental toxoplasmosis in mice. PLoS One10:e0143087. doi:10.1371/journal.pone.0143087. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science282:2085–2088. doi:10.1126/science.282.5396.2085. [PubMed] [CrossRef] [Google Scholar]
37. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol3:667–672. doi:10.1038/ni809. [PubMed] [CrossRef] [Google Scholar]
38. Petsch D, Anspach FB. 2000. Endotoxin removal from protein solutions. J Biotechnol76:97–119. doi:10.1016/S0168-1656(99)00185-6. [PubMed] [CrossRef] [Google Scholar]
39. Anspach FB, Hilbeck O. 1995. Removal of endotoxins by affinity sorbents. J Chromatogr A711:81–92. doi:10.1016/0021-9673(95)00126-8. [PubMed] [CrossRef] [Google Scholar]
40. Mandrekar JN. 2010. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol5:1315–1316. doi:10.1097/JTO.0b013e3181ec173d. [PubMed] [CrossRef] [Google Scholar]
41. Mandrekar JN. 2010. Simple statistical measures for diagnostic accuracy assessment. J Thorac Oncol5:763–764. doi:10.1097/JTO.0b013e3181dab122. [PubMed] [CrossRef] [Google Scholar]
42. Hughes HP, van Knapen F. 1982. Characterisation of a secretory antigen from Toxoplasma gondii and its role in circulating antigen production. Int J Parasitol12:433–437. doi:10.1016/0020-7519(82)90073-X. [PubMed] [CrossRef] [Google Scholar]
43. Rougier D, Ambroise-Thomas P. 1985. Detection of toxoplasmic immunity by multipuncture skin test with excretory-secretory antigen. Lancetii:121–123. [PubMed] [Google Scholar]
44. Cardolfi E, Bessieres MH, Marty P, Cimon B, Gandilhon F, Pelloux H, Thulliez P. 1993. Determination of a new cut-off value for the diagnosis of congenital toxoplasmosis by detection of specific IgM in an enzyme immunoassay. Eur J Clin Microbiol Infect Dis12:396–398. doi:10.1007/BF01964443. [PubMed] [CrossRef] [Google Scholar]
45. Remington JS, Araujo FG, Desmonts G. 1985. Recognition of different Toxoplasma antigens by IgM and IgG antibodies in mothers and their congenitally infected newborns. J Infect Dis152:1020–1024. doi:10.1093/infdis/152.5.1020. [PubMed] [CrossRef] [Google Scholar]
46. Li S, Maine G, Suzuki Y, Araujo FG, Galvan G, Remington JS, Parmley S. 2000. Serodiagnosis of recently acquired Toxoplasma gondiiinfection with a recombinant antigen. J Clin Microbiol 38:179–184. [PMC free article] [PubMed] [Google Scholar]
47. Turunen H, Vuorio KA, Leinikki PO. 1983. Determination of IgG, IgM and IgA antibody responses in human toxoplasmosis by enzyme-linked immunosorbent assay (ELISA). Scand J Infect Dis15:307–311. doi:10.3109/inf.1983.15.issue-3.12. [PubMed] [CrossRef] [Google Scholar]
48. Villard O, Cimon B, L'Ollivier C, Fricker-Hidalgo H, Godineau N, Houze S, Paris L, Pelloux H, Villena I, Candolfi E. 2016. Serological diagnosis of Toxoplasma gondii infection: recommendations from the French National Reference Center for Toxoplasmosis. Diagn Microbiol Infect Dis84:22–33. doi:10.1016/j.diagmicrobio.2015.09.009. [PubMed] [CrossRef] [Google Scholar]
49. Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, Stoehr A, Horst HA, Marienfeld K, Lange C. 2007. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect13:510–515. doi:10.1111/j.1469-0691.2007.01683.x. [PubMed] [CrossRef] [Google Scholar]
50. Chapey E, Wallon M, Debize G, Rabilloud M, Peyron F. 2010. Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay. J Clin Microbiol48:41–45. doi:10.1128/JCM.01903-09. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
51. Ciardelli L, Meroni V, Avanzini MA, Bollani L, Tinelli C, Garofoli F, Gasparoni A, Stronati M. 2008. Early and accurate diagnosis of congenital toxoplasmosis. Pediatr Infect Dis J27:125–129. doi:10.1097/INF.0b013e3181586052. [PubMed] [CrossRef] [Google Scholar]
52. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV. 2001. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet357:2017–2021. doi:10.1016/S0140-6736(00)05115-1. [PubMed] [CrossRef] [Google Scholar]
53. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. 2004. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet364:2196–2203. doi:10.1016/S0140-6736(04)17592-2. [PubMed] [CrossRef] [Google Scholar]
54. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A. 2001. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol167:5217–5225. doi:10.4049/jimmunol.167.9.5217. [PubMed] [CrossRef] [Google Scholar]
55. Yin Q, El-Ashram S, Liu H, Sun X, Zhao X, Liu X, Suo X. 2015. Interferon-gamma release assay: an effective tool to detect early Toxoplasma gondii infection in mice. PLoS One10:e0137808. doi:10.1371/journal.pone.0137808. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
56. Fatoohi AF, Cozon GJ, Greenland T, Ferrandiz J, Bienvenu J, Picot S, Peyron F. 2002. Cellular immune responses to recombinant antigens in pregnant women chronically infected with Toxoplasma gondii. Clin Diagn Lab Immunol9:704–707. [PMC free article] [PubMed] [Google Scholar]
57. Khan IA, Green WR, Kasper LH, Green KA, Schwartzman JD. 1999. Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host. Infect Immun67:5869–5876. [PMC free article] [PubMed] [Google Scholar]
58. Miller R, Wen X, Dunford B, Wang X, Suzuki Y. 2006. Cytokine production of CD8+ immune T cells but not of CD4+ T cells from Toxoplasma gondii-infected mice is polarized to a type 1 response following stimulation with tachyzoite-infected macrophages. J Interferon Cytokine Res26:787–792. doi:10.1089/jir.2006.26.787. [PubMed] [CrossRef] [Google Scholar]
59. Grover HS, Blanchard N, Gonzalez F, Chan S, Robey EA, Shastri N. 2012. The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infect Immun80:3279–3288. doi:10.1128/IAI.00425-12. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Bhadra R, Gigley JP, Khan IA. 2012. PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic toxoplasma infection. J Infect Dis206:125–134. doi:10.1093/infdis/jis304. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Kaech SM, Wherry EJ. 2007. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity27:393–405. doi:10.1016/j.immuni.2007.08.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
62. Martin DL, Tarleton RL. 2005. Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol174:1594–1601. doi:10.4049/jimmunol.174.3.1594. [PubMed] [CrossRef] [Google Scholar]
63. Stephens R, Langhorne J. 2010. Effector memory Th1 CD4 T cells are maintained in a mouse model of chronic malaria. PLoS Pathog6:e1001208. doi:10.1371/journal.ppat.1001208. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
64. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med15:293–299. doi:10.1038/nm.1935. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. Starnes GL, Coincon M, Sygusch J, Sibley LD. 2009. Aldolase is essential for energy production and bridging adhesin-actin cytoskeletal interactions during parasite invasion of host cells. Cell Host Microbe5:353–364. doi:10.1016/j.chom.2009.03.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
66. National Research Council. 2011. Guide for the Care and Use of Laboratory Animals, 8th ed The National Academies Press, Washington, DC: 5:353–364. doi:10.17226/12910. [CrossRef] [Google Scholar]

Articles from mSphere are provided here courtesy of American Society for Microbiology (ASM)